Cite
HARVARD Citation
Janku, F. et al. (n.d.). Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. European journal of cancer. pp. S11-. [Online].